mRNA Drug Targeting CD19 for Blood Cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your doctor expects you to live at least 12 more weeks.
- You have been diagnosed with B-cell lymphoma or B-cell leukemia that has the CD19 protein on the cancer cells.
- You have tried standard treatments and they are no longer working or are not right for you.
- You are generally able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T therapy (a treatment that uses your own immune cells, genetically changed to attack cancer) that targets a protein called CD20 found on some blood cancer cells. It's for people with B-cell lymphoma or lymphocytic leukemia who have already had other treatments and need a new option.
This study tests a new mRNA treatment that targets CD19, a protein on some immune cells that cause autoimmune diseases. It aims to help people with severe or treatment-resistant autoimmune diseases like immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma, where the immune system attacks the body's own tissues.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This study tests a new kind of treatment called LNP-mRNA that targets specific cells involved in autoimmune diseases like lupus. It might help reset your immune system if standard treatments haven't worked.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.